For: | Bouziana SD, Tziomalos K. Clinical relevance of clopidogrel-proton pump inhibitors interaction. World J Gastrointest Pharmacol Ther 2015; 6(2): 17-21 [PMID: 25949846 DOI: 10.4292/wjgpt.v6.i2.17] |
---|---|
URL: | https://www.wjgnet.com/2150-5349/full/v6/i2/17.htm |
Number | Citing Articles |
1 |
Riley Batchelor, Radya Kumar, Julia F. M. Gilmartin‐Thomas, Ingrid Hopper, William Kemp, Danny Liew. Systematic review with meta‐analysis: risk of adverse cardiovascular events with proton pump inhibitors independent of clopidogrel. Alimentary Pharmacology & Therapeutics 2018; 48(8): 780 doi: 10.1111/apt.14955
|
2 |
Arghya Datta, Matthew K. Matlock, Na Le Dang, Thiago Moulin, Keith F. Woeltje, Elizabeth L. Yanik, Sanjay Joshua Swamidass. ‘Black Box’ to ‘Conversational’ Machine Learning: Ondansetron Reduces Risk of Hospital-Acquired Venous Thromboembolism. IEEE Journal of Biomedical and Health Informatics 2021; 25(6): 2204 doi: 10.1109/JBHI.2020.3033405
|
3 |
Alex M. Lynch, Laura K. Ruterbories, Emily Griffith, Rita M. Hanel, Alyssa P. Stablein, Marjory B. Brooks. The influence of feeding and gastroprotectant medications on the Factor Xa inhibitory activity of orally administered rivaroxaban in normal dogs. Journal of Veterinary Emergency and Critical Care 2021; 31(1): 59 doi: 10.1111/vec.13019
|
4 |
Mohammadreza Amirsadri, Valiollah Hajhashemi, Amir Shahriar Asemi. Cost-Effectiveness and Cost–Utility Analysis of the Use of Clopidogrel and Pantoprazole in Comparison with Clopidogrel and Omeprazole for the Secondary Prevention of Myocardial Infarction in Iran. Journal of Research in Pharmacy Practice 2021; 10(2): 90 doi: 10.4103/jrpp.JRPP_21_22
|
5 |
Julio D. Duarte, Larisa H. Cavallari. Pharmacogenetics to guide cardiovascular drug therapy. Nature Reviews Cardiology 2021; 18(9): 649 doi: 10.1038/s41569-021-00549-w
|
6 |
Agnieszka Wiesner, Małgorzata Zwolińska-Wcisło, Paweł Paśko. Effect of Food and Dosing Regimen on Safety and Efficacy of Proton Pump Inhibitors Therapy—A Literature Review. International Journal of Environmental Research and Public Health 2021; 18(7): 3527 doi: 10.3390/ijerph18073527
|
7 |
Wengen Zhu, Kui Hong. Potential Cardiovascular Risks of Proton Pump Inhibitors in the General Population. International Heart Journal 2017; 58(2): 163 doi: 10.1536/ihj.16-208
|
8 |
Renan Sukmawan, Erick Hoetama, Siska Suridanda Danny, Astuti Giantini, Erlin Listiyaningsih, Vidya Gilang Rejeki, Amir Aziz Alkatiri, Isman Firdaus. Increase in the risk of clopidogrel resistance and consequent TIMI flow impairment by DNA hypomethylation of CYP2C19 gene in STEMI patients undergoing primary percutaneous coronary intervention (PPCI). Pharmacology Research & Perspectives 2021; 9(2) doi: 10.1002/prp2.738
|
9 |
Troy J. Smith, Jessica L. Johnson, Abiy Habtewold, Melissa A. Burmeister. Cardiovascular Risk Reduction. Critical Care Nursing Clinics of North America 2019; 31(1): 15 doi: 10.1016/j.cnc.2018.11.001
|
10 |
Evence Daure, Linda Ross, Cynthia R. L. Webster. Gastroduodenal Ulceration in Small Animals: Part 2. Proton Pump Inhibitors and Histamine-2 Receptor Antagonists. Journal of the American Animal Hospital Association 2017; 53(1): 11 doi: 10.5326/JAAHA-MS-6634
|
11 |
Himawan Fernando, James A. Shaw, Paul S. Myles, Karlheinz Peter, Dion Stub. The opioid-P2Y12 inhibitor interaction: Potential strategies to mitigate the interaction and consideration of alternative analgesic agents in myocardial infarction. Pharmacology & Therapeutics 2021; 217: 107665 doi: 10.1016/j.pharmthera.2020.107665
|
12 |
Ming-Ying Ai, Yan-Zuo Chen, Chien-Liang Kuo, Wei-Lun Chang. A network meta-analysis: evaluating the efficacy and safety of concurrent proton pump inhibitors and clopidogrel therapy in post-PCI patients. Frontiers in Cardiovascular Medicine 2024; 11 doi: 10.3389/fcvm.2024.1385318
|
13 |
Samuel P. Banting, Henry E. Badgery, Matthew Read, Hiroshi Mashimo. Rethinking gastroesophageal reflux disorder. Annals of the New York Academy of Sciences 2020; 1482(1): 177 doi: 10.1111/nyas.14478
|
14 |
Daniela Jodorkovsky, John W. Blackett. Laryngopharyngeal and Gastroesophageal Reflux. 2020; : 271 doi: 10.1007/978-3-030-48890-1_30
|
15 |
Christina Plante, Pamela M. Lee, Jillian M. Haines, O. Lynne Nelson, Stephanie E. Martinez, Michael H. Court. The effect of concurrent clopidogrel and omeprazole administration on clopidogrel metabolism and platelet function in healthy cats. Journal of Veterinary Internal Medicine 2024; doi: 10.1111/jvim.17198
|
16 |
Natalia Cichoń, Dominika Lach, Michał Bijak Bijak, Paulina Rzeźnicka, Joanna Saluk. PODOBIEŃSTWA I RÓŻNICE W TERAPIACH PRZECIWPŁYTKOWYCH W OSTRYCH ZESPOŁACH WIEŃCOWYCH I UDARZE NIEDOKRWIENNYM MÓZGU. Prospects in Pharmaceutical Sciences 2016; 14(4): 25 doi: 10.56782/pps.108
|
17 |
Joshua S Catapano, Visish M Srinivasan, Andre A Wakim, Jaclyn N Lundberg, Caleb Rutledge, Tyler S Cole, Jacob F Baranoski, Vance L Fredrickson, Redi Rahmani, Felipe C Albuquerque, Andrew F Ducruet. Omeprazole-clopidogrel interaction and neurovascular complications after flow-diverter device placement. Journal of NeuroInterventional Surgery 2022; 14(4): 380 doi: 10.1136/neurintsurg-2021-017397
|
18 |
Sujit B. Bhalekar, Sharad N. Shelke. Synthesis, Biological and Molecular Docking Study of Benzimidazole‐Clubbed Tetrahydrothieno [3, 2‐c] Pyridine as Platelet Inhibitors. ChemistrySelect 2019; 4(41): 12170 doi: 10.1002/slct.201902916
|
19 |
Priyadharshini Ananthathandavan, Damodharan Narayanasamy. Computational drug–drug interaction prediction mediated by CYP450 isoforms of Ilaprazole coadministered with clopidogrel. Future Science OA 2024; 10(1) doi: 10.2144/fsoa-2023-0277
|